

## Financial Tear Sheet


### Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

### Stock Performance

| AMGN (COMMON STOCK) |                    |
|---------------------|--------------------|
| Exchange            | NASDAQ (US Dollar) |
| Price               | \$174.92           |
| Change (%)          | ▼ 2.46 (1.39%)     |
| Volume              | 2,723,557          |
| 52 Week Low         | \$145.12           |
| Market Cap          | \$126,976,277,779  |
| Rolling EPS         | 11.07              |
| PE Ratio            | 15.8               |
| Shares Outstanding  | 725,910,575        |



Data as of 12/14/17 4:00 p.m. ET

## Recent Headlines

12/14/17

Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

12/12/17

Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend

12/11/17


KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

## Upcoming Events

There are currently no events scheduled.

## Analyst Estimates / Ratings

Mean Recommendation: **2.4**



### EPS TREND

|     |        | Current | 30 Days Ago | 90 Days Ago |
|-----|--------|---------|-------------|-------------|
| QTR | Dec 17 | 3.01    | 3.01        | 3.08        |
| QTR | Mar 18 | 3.14    | 3.14        | 3.14        |
| QTR | Jun 18 | 3.19    | 3.19        | 3.13        |
| QTR | Sep 18 | 3.17    | 3.17        | 3.08        |
| FY  | Dec 17 | 12.67   | 12.67       | 12.57       |
| FY  | Dec 18 | 12.75   | 12.75       | 12.79       |

## SEC Filings

| FILING DATE | FORM     |
|-------------|----------|
| 12/12/17    | 4        |
| 12/12/17    | 3        |
| 12/04/17    | CT ORDER |
| 11/14/17    | 4        |

## Financial Reports

Q3 2017 Financial Results

## Presentations

12/09/17 ASH Conference Presentation

*Data provided by Nasdaq. Minimum 15 minutes delayed.*